Research analysts at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a report issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
GLMD opened at $0.29 on Wednesday. The stock has a market cap of $1.45 million, a price-to-earnings ratio of -0.12 and a beta of 0.69. The stock’s 50 day moving average price is $0.31 and its 200-day moving average price is $0.35. Galmed Pharmaceuticals has a one year low of $0.26 and a one year high of $0.90.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last released its earnings results on Thursday, May 30th. The biopharmaceutical company reported ($0.23) EPS for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- What is the Euro STOXX 50 Index?
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- NYSE Stocks Give Investors a Variety of Quality Options
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
